王曼丽

研究方向

1. 高致病性病毒感染及致病机制

2. 抗病毒药物研究

3. 病毒载体的改造及应用

教育及工作经历

1998.09 – 2002.07 武汉工业学院，生物工程，学士

2002.09 – 2008.09 中国科学院武汉病毒研究所，微生物学，博士

2007.03 – 2007.10 Wageningen大学，病毒系，访问学者（受中国科学院－荷兰皇家科学院战略联盟计划PSA资助） 

2008.10 – 2011.08 中国科学院武汉病毒研究所，系统病毒学学科组，助理研究员

2011.09 – 2019.08 中国科学院武汉病毒研究所，系统病毒学学科组，副研究员

2019.09 – 至今     中国科学院武汉病毒研究所，研究员

近五年承担项目

1.国家重点研发计划“潜在虫媒新病毒的传播和致病机制研究”（2023YFC2305900），2023.12-2026.11，100万元

2.国家重点研发计划“重要致病原及突变株的疫苗及药物有效性评价的动物模型体系建设和应用”（2021YFC2301700），2021.12-2024.12，253万元

3.国家自然科学基金面上项目“大DNA病毒Erv巯基氧化酶的结构和功能相关性研究”（32370182），2024.1-2027.12，直接经费50万元

4.国家自然科学基金-云南区域重点项目“云南及跨境地区流行性出血热的传播规律、发病机理与防治研究”（U2202216），2023.1-2026.12，直接经费72万元

5.国家自然科学基金国际合作与交流项目（中国-保加利亚），82061138021，利用纳米受限技术开展可控细胞毒性的抗冠状病毒新型杂环化合物分子设计、合成及评价，2021/01-2022/12，177.12万元

近五年代表性论文

1. Li L, Chong T, Peng L, Liu Y, Rao G, Fu Y, Shu Y, Shen J, Xiao Q, Liu J, Li J, Deng F, Yan B, Hu Z, Cao S, Wang M*. Neutralizing monoclonal antibodies against the Gc fusion loop region of Crimean-Congo hemorrhagic fever virus. PLoS Pathog. 2024. 20:e1011948.

2. Liu J, Wang F, Wang X, Fan S, Li Y, Xu M, Hu H, Liu K, Zheng B, Wang L, Zhang H, Li J, Li W, Zhang W, Hu Z, Cao R, Zhuang X, Wang M*, Zhong W*. Antiviral effects and tissue exposure of tetrandrine against SARS-CoV-2 infection and COVID-19. MedComm. 2020. 2023.4:e206.

3. Yin M, Kuang W, Wang Q, Wang X, Yuan C, Lin Z, Zhang H, Deng F, Jiang H, Gong P*, Zou Z*, Hu Z*, Wang M*. Dual roles and evolutionary implications of P26/poxin in antagonizing intracellular cGAS-STING and extracellular melanization immunity. Nat Commun. 2022 13:6934.

4. Ma J#, Liu J#, Gao D#, Li X#, Zhang Q, Lv L, Wang Y, Li J, Zhu Y, Wu Z, Hu H, Li Y, Ma L, Liu Q, Hu Z, Zhang S*, Zhou Y*, Wang M*, Leng L*. Establishment of Human Pluripotent Stem Cell-Derived Skin Organoids Enabled Pathophysiological Model of SARS-CoV-2 Infection. Adv Sci . 2022. 9:e2104192.

5. Wang Q, Cao R, Li L, Liu J, Yang J, Li W, Yan L, Wang Y, Yan Y, Li J, Deng F, Zhou Y, Wang M*, Zhong W*, Hu Z*. In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean-Congo hemorrhagic fever virus. Antiviral Res. 2022. 199:105273. 

6. Han Y, Yang Z, Hu H, Zhang H, Chen L, Li K, Kong L, Wang Q, Liu B, Wang M*, Lin J*, Chen PR*. Covalently Engineered Protein Minibinders with Enhanced Neutralization Efficacy against Escaping SARS-CoV-2 Variants. J Am Chem Soc. 2022.144:5702-5707. 

7. Hu H, Pan K, Shang Y, Guo Y, Xiao H, Deng F, Wang M*, Hu Z*. Multiloci Manipulation of Baculovirus Genome Reveals the Pivotal Role of Homologous Regions in Viral DNA Replication, Progeny Production, and Enhancing Transcription. ACS Synth Biol. 2022.11:144-153. 

8. Yu D, Li YF, Liang H, Wu JZ, Hu Y, Peng Y, Li TJ, Hou JF, Huang WJ, Guan LD, Han R, Xing YT, Zhang Y, Liu J, Feng L, Li CY, Liang XL, Ding YL, Zhou ZJ, Ji DM, Wang FF, Yu JH, Deng K, Xia DM, Dong DM, Hu HR, Liu YJ, Fu DX, He YL, Zhou DB, Yang HC, Jia R, Ke CW, Du T, Xie Y, Zhou R, Li CS, Wang ML*, Yang XM*. Potent Anti-SARS-CoV-2 Efficacy of COVID-19 Hyperimmune Globulin from Vaccine-Immunized Plasma. Adv Sci. 2022. 9:e2104333. 

9. Liu J#, Li Y#, Liu Q#, Yao Q#, Wang X, Zhang H, Chen R, Ren L, Min J, Deng F, Yan B, Liu L, Hu Z*, Wang M*, Zhou Y*. SARS-CoV-2 cell tropism and multiorgan infection. Cell Discovery 2021. 7:17. 

10. Leng L#, Cao R#, Ma J#, Lv L#, Li W#, Zhu Y*, Wu Z*, Wang M*, Zhou Y*, Zhong W*. Pathological features of COVID-19-associated liver injury-a preliminary proteomics report based on clinical samples. Signal Transduct Target Ther. 2021.6:9. 10.1038/s41392-020-00406-1

11. Fu D#, Zhang G#, Wang Y#, Zhang Z#, Hu H#, Shen S#, Wang J#, Li B#, Li X#, Fang Y, Liu J, Wang Q, Zhou Y, Wang W, Li Y, Lu Z, Wang X, Nie C, Tian Y, Chen D, Wang Y, Zhou X, Wang Q, Yu F, Zhang C, Deng C, Zhou L, Guan G, Shao N, Lou Z*, Deng F*, Zhang H*, Chen X*, Wang M*, Liu L*, Rao Z*, Guo Y*. Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes. PloS Biology. 2021.19:e3001209. 

12. Wang M#, Cao R#, Zhang L#, Yang X#, Liu J, Xu M, Shi Z, Hu Z*, Zhong W*, Xiao G*. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020.30:269-271. (F1000prime收录推荐)

13. Liu J#, Cao R#, Xu M#, Wang X, Zhang H, Hu H, Li Y, Hu Z*, Zhong W*, Wang M*. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery. 2020. 6:16. (F1000prime收录推荐)

14. Wang X#, Cao R#, Zhang H#, Liu J, Xu M, Hu H, Li Y, Zhao L, Li W, Sun X, Yang X, Shi Z, Deng F, Hu Z*, Zhong W*, Wang M*. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discovery. 2020. 6:28. 

15. Liu J#, Li Y#, Liu L#. Hu X, Wang X, Hu H, Hu Z, Zhou Y*, Wang M*. Infection of human sweat glands by SARS-CoV-2. Cell Discovery. 2020. 6: 84. 

16. Li Y, Hu L, Chen T, Chang M, Deng F, Hu Z, Wang H*, Wang M*. Host AAA+ ATPase TER94 Plays Critical Roles in Building the Baculovirus Viral Replication Factory and Virion Morphogenesis. J Virol. 2020. 94: e01674-19. 

17. Shao W#, He L, Deng F, Wang H, Vlak JM, Hu Z*, Wang M*. Mito‐docking: A Novel In Vivo Method to Detect Protein–Protein Interactions. Small Methods. 2019.3:1900010. 

18. Hu L, Li Y, Ning YJ, Deng F, Vlak JM, Hu Z, Wang H*, Wang M*. The major hurdle for effective baculovirus transduction into mammalian cells is passing early endosomes. J Virol. 2019.93:e00709-19. 

19. Liu J, Xu M, Tang B, Hu L, Deng F, Wang H, Pang DW, Hu Z, Wang M*, Zhou Y*. Single-Particle Tracking Reveals the Sequential Entry Process of the Bunyavirus Severe Fever with Thrombocytopenia Syndrome Virus. Small. 2019.15:e1803788.

20. Zhang L, Wang B, Xin Q, Shang W, Shen S, Xiao G, Deng F, Wang H, Hu Z*, Wang M*. Quantitative proteomic analysis reveals unfolded protein response involved in severe fever with thrombocytopenia syndrome virus infection. J Virol. 2019.93: e00308-19.